Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims

• Pfizer Inc (NYSE: PFE) and its partner, BioNTech SE (NASDAQ: BNTX), said that they developed their vaccine independently, refuting Moderna Inc's (NASDAQ: MRNA) patent claims.

• In August, Moderna filed patent infringement lawsuits saying Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology critical in creating Moderna's mRNA COVID-19 vaccine.

• Pfizer called Moderna's lawsuit "revisionist history" and argued its patents "far exceed its actual contributions to the field."

• A Pfizer spokesperson said the company and BioNTech are confident in their intellectual property and will "vigorously defend" against Moderna's claims.

• Related: Moderna Shares Deep Dive After Lower COVID-19 Vaccine Sales Weigh On Q3 Sales, Profits.

• In its lawsuit, Moderna asked for an undisclosed amount of money damages from Pfizer COVID-19 vaccines sold since March.

• The companies argued that Moderna ignored the contributions of their scientists to foundational mRNA technology, as well as those of researchers at the U.S. government's National Institutes of Health.

• Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and Arbutus Biopharma Corporation (NASDAQ: ABUS) have lawsuits against Moderna regarding its COVID-19 vaccine.

• Price Action: MRNA shares are down 0.75% at $174.61 during the premarket session on the last check Tuesday.

See more from Benzinga

• European Official Says COVID-19 Booster Uptake Disappointing In The Region

• Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.